Company unveils Parkinson’s disease associated with GBA mutations (PD-GBA) program; two oral presentations feature new data from Capsida’s wholly owned programs in PD-GBA and genetic epilepsy due to STXBP1 mutations; both programs in IND-enabling studies to support initiation of clinical…

WALTHAM, Mass., April 22, 2024 /PRNewswire/ — Affinia Therapeutics (“Affinia”), an innovative gene therapy company with a proprietary platform for rationally designed adeno-associated virus (AAV) vectors and gene therapies for rare and prevalent devastating diseases, today announced that…

Total passenger traffic in 1Q24 increased 3.9% YoY MEXICO CITY, April 22, 2024 /PRNewswire/ — Grupo Aeroportuario del Sureste, S.A.B. de C.V. (NYSE: ASR; BMV: ASUR) (ASUR), a leading international airport group with operations in Mexico, the U.S., and Colombia, today announced results…

Privacy Overview

This website uses cookies so that we can provide you with the best user experience possible. Cookie information is stored in your browser and performs functions such as recognising you when you return to our website and helping our team to understand which sections of the website you find most interesting and useful.